Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$1.22
-2.4%
$1.21
$0.92
$22.50
$72.93M0.61309,982 shs103,956 shs
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$0.94
+2.6%
$0.79
$0.52
$5.17
$79.76M1.771.10 million shs1.04 million shs
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
$1.00
-3.8%
$1.49
$0.96
$4.30
$15.21M1.76112,580 shs318,117 shs
Zura Bio Limited stock logo
ZURA
Zura Bio
$1.00
-2.0%
$1.24
$0.97
$5.56
$68.38M0.05409,539 shs565,550 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-2.40%-1.61%-7.58%-6.87%-87.23%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
+2.64%+4.96%+4.62%-41.35%-77.19%
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-3.85%-13.04%-30.07%-60.78%-61.24%
Zura Bio Limited stock logo
ZURA
Zura Bio
-1.96%-6.54%-27.01%-19.35%-81.79%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
4.1015 of 5 stars
3.02.00.04.62.03.31.3
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
4.4427 of 5 stars
4.13.00.04.72.81.70.6
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
2.6641 of 5 stars
3.53.00.00.03.31.70.6
Zura Bio Limited stock logo
ZURA
Zura Bio
2.6607 of 5 stars
3.62.00.00.03.22.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
1.90
Reduce$5.50350.82% Upside
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
2.13
Hold$6.11547.49% Upside
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
3.00
Buy$6.25525.00% Upside
Zura Bio Limited stock logo
ZURA
Zura Bio
3.13
Buy$14.331,333.33% Upside

Current Analyst Ratings Breakdown

Latest VYNE, STRO, IGMS, and ZURA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$1.00 ➝ $0.80
5/9/2025
Zura Bio Limited stock logo
ZURA
Zura Bio
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$19.00 ➝ $17.00
4/29/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00
4/25/2025
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.75 ➝ $4.50
4/3/2025
Zura Bio Limited stock logo
ZURA
Zura Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/3/2025
Zura Bio Limited stock logo
ZURA
Zura Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$5.00 ➝ $3.00
3/26/2025
Zura Bio Limited stock logo
ZURA
Zura Bio
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$20.00 ➝ $19.00
3/26/2025
Zura Bio Limited stock logo
ZURA
Zura Bio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
3/26/2025
Zura Bio Limited stock logo
ZURA
Zura Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $10.00
3/17/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$12.00 ➝ $2.00
3/14/2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$2.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$2.68M27.20N/AN/A$3.46 per share0.35
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$66.43M1.20N/AN/A$2.45 per share0.39
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
$605K25.14N/AN/A$6.36 per share0.16
Zura Bio Limited stock logo
ZURA
Zura Bio
N/AN/AN/AN/A$1.85 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$246.42M-$3.27N/AN/AN/A-7,534.03%-155.42%-61.04%8/13/2025 (Estimated)
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$106.79M-$2.98N/AN/AN/A-77.01%-101.89%-28.69%8/12/2025 (Estimated)
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-$28.45M-$0.99N/AN/AN/A-6,896.55%-43.73%-38.55%8/13/2025 (Estimated)
Zura Bio Limited stock logo
ZURA
Zura Bio
-$69.24M-$0.70N/AN/AN/AN/A-37.36%-29.81%8/12/2025 (Estimated)

Latest VYNE, STRO, IGMS, and ZURA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$0.41-$0.86-$0.45-$0.86$4.25 million$0.50 million
5/8/2025Q1 2025
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$0.63-$0.91-$0.28-$0.91$11.61 million$17.40 million
5/8/2025Q1 2025
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-$0.29-$0.20+$0.09-$0.20$0.05 million$0.20 million
5/8/2025Q1 2025
Zura Bio Limited stock logo
ZURA
Zura Bio
-$0.17-$0.19-$0.02-$0.19N/AN/A
3/25/2025Q4 2024
Zura Bio Limited stock logo
ZURA
Zura Bio
-$0.17-$0.08+$0.09-$0.08N/A$0.00 million
3/13/2025Q4 2024
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$0.86-$2.96-$2.10-$0.89$10.44 million$14.00 million
3/6/2025Q4 2024
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$0.74-$0.61+$0.13-$0.61$0.39 million$0.41 million
3/6/2025Q4 2024
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
-$0.31-$0.28+$0.03-$0.28$0.14 million$0.08 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/AN/AN/AN/AN/A
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
N/AN/AN/AN/AN/A
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
N/AN/AN/AN/AN/A
Zura Bio Limited stock logo
ZURA
Zura Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/A
5.22
5.22
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
N/A
3.09
3.09
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
N/A
5.81
5.81
Zura Bio Limited stock logo
ZURA
Zura Bio
N/A
10.36
10.36

Institutional Ownership

CompanyInstitutional Ownership
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
42.79%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
96.99%
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
83.78%
Zura Bio Limited stock logo
ZURA
Zura Bio
61.14%

Insider Ownership

CompanyInsider Ownership
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
57.00%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
3.60%
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
4.80%
Zura Bio Limited stock logo
ZURA
Zura Bio
14.23%
CompanyEmployeesShares OutstandingFree FloatOptionable
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
19059.78 million25.57 millionOptionable
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
24084.46 million77.59 millionOptionable
VYNE Therapeutics Inc. stock logo
VYNE
VYNE Therapeutics
3015.21 million14.04 millionNot Optionable
Zura Bio Limited stock logo
ZURA
Zura Bio
368.38 million50.86 millionOptionable

Recent News About These Companies

What is HC Wainwright's Forecast for Zura Bio Q2 Earnings?
What is HC Wainwright's Forecast for Zura Bio Q1 Earnings?
Zura Bio price target lowered to $3 from $5 at H.C. Wainwright
Zura Bio (ZURA) Gets a Buy from Guggenheim

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
IGM Biosciences stock logo

IGM Biosciences NASDAQ:IGMS

$1.22 -0.03 (-2.40%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.18 -0.03 (-2.87%)
As of 05:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Sutro Biopharma stock logo

Sutro Biopharma NASDAQ:STRO

$0.94 +0.02 (+2.64%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$0.94 -0.01 (-0.56%)
As of 05/27/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

VYNE Therapeutics stock logo

VYNE Therapeutics NASDAQ:VYNE

$1.00 -0.04 (-3.85%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.05 +0.05 (+4.70%)
As of 05/27/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Zura Bio stock logo

Zura Bio NASDAQ:ZURA

$1.00 -0.02 (-1.96%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.04 +0.04 (+4.00%)
As of 06:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.